
News|Articles|November 18, 2024
Elevating and De-Risking Your Drug Portfolio Strategy With AI
Author(s)Intelligencia AI
Artificial intelligence (AI) can improve risk assessment and decision-making in drug development by applying objective, data-driven criteria consistently. Companies should focus on the quality of data, selecting the right AI use cases, and leveraging external partners to maximize the potential of AI.
Trending on PharmExec
1
FDA Pannel Votes to Loosen Restrictions for Four Peptides
2
Retatrutide Delivers Up to 22.6% Weight Loss in Two New Phase III Trials
3
Pharmaceutical Executive Daily: Eli Lilly Reports Positive Results from Two Phase III Trials
4
GLP-1’s Cardiometabolic Benefit and the Impact on Coverage
5